Atara Biotherapeutics (ATRA) News Today $8.82 +0.11 (+1.26%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$8.80 -0.03 (-0.28%) As of 05:34 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ATRA Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Millennium Management LLC Has $135,000 Stock Position in Atara Biotherapeutics, Inc. (NASDAQ:ATRA)Millennium Management LLC lessened its stake in shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Free Report) by 94.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,133 shares of the biotechJune 13 at 3:07 AM | marketbeat.comAtara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Consensus Rating of "Moderate Buy" by AnalystsAtara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) has been given an average recommendation of "Moderate Buy" by the seven ratings firms that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have given a hold rating, three have asJune 6, 2025 | marketbeat.comRedmile Group, LLC's Strategic Acquisition in Atara Biotherapeutics IncMay 29, 2025 | gurufocus.comYanina Grant-Huerta Sells 2,218 Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) StockMay 21, 2025 | insidertrades.comAtara Biotherapeutics appoints Huang, Subramanian to board of directorsMay 18, 2025 | msn.comAtara Biotherapeutics sets stock and warrant offering pricesMay 17, 2025 | investing.comAtara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of DirectorsMay 16, 2025 | businesswire.comAtara Biotherapeutics Announces Pricing of $16 Million OfferingMay 15, 2025 | finance.yahoo.comAtara Biotherapeutics Announces First Quarter Financial Results and Operational ProgressMay 15, 2025 | businesswire.comAtara Biotherapeutics Says FDA Lifts Clinical HoldMay 5, 2025 | marketwatch.comAtara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel)May 5, 2025 | finance.yahoo.comAtara Biotherapeutics (ATRA) Receives a Buy from TD CowenMarch 10, 2025 | markets.businessinsider.comAtara Biotherapeutics Faces Potential Liquidation: Strategic Decisions Crucial for Investor OutcomesMarch 9, 2025 | tipranks.comAtara Biotherapeutics to Cut Half of Workforce Amid RestructuringMarch 8, 2025 | marketwatch.comAtara Biotherapeutics reports Q4 EPS ($1.19) vs. ($14.00) last yearMarch 8, 2025 | markets.businessinsider.comAtara Biotherapeutics Reports 2024 Financial ResultsMarch 7, 2025 | tipranks.comAtara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational ProgressMarch 7, 2025 | businesswire.comAnhco Nguyen Sells 3,331 Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) StockMarch 6, 2025 | insidertrades.comWolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities lawsFebruary 14, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRAFebruary 11, 2025 | prnewswire.comAtara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)February 7, 2025 | businesswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRAFebruary 4, 2025 | prnewswire.comWolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities lawsFebruary 3, 2025 | globenewswire.comAtara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Consensus Recommendation of "Moderate Buy" by AnalystsAtara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the seven research firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hoFebruary 1, 2025 | marketbeat.comWolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities lawsJanuary 30, 2025 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRAJanuary 28, 2025 | prnewswire.comAtara stock holds Neutral rating after workforce cutJanuary 28, 2025 | msn.comATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc. Securities Fraud Investigation with the Schall Law FirmJanuary 28, 2025 | prnewswire.comAtara reduction in workforce to impact 50% of current employeesJanuary 27, 2025 | msn.comAtara to cut 50% of workforce amid FDA woesJanuary 27, 2025 | msn.comATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc. Securities Fraud Investigation with the Schall Law FirmJanuary 27, 2025 | businesswire.comAtara Biotherapeutics Faces Strategic Uncertainty Amid FDA Hold and CRL IssuesJanuary 23, 2025 | markets.businessinsider.comAtara Biotherapeutics price target lowered to $5 from $10 at StifelJanuary 22, 2025 | markets.businessinsider.comStifel cuts Atara Biotherapeutics target to $5, holds ratingJanuary 21, 2025 | msn.comAtara Biotherapeutics Faces Uncertainty Amid FDA Clinical Hold and Financing Needs, Resulting in Hold RatingJanuary 21, 2025 | markets.businessinsider.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRAJanuary 21, 2025 | prnewswire.comUS FDA puts clinical hold on Atara's trials for cancer cell therapiesJanuary 21, 2025 | reuters.comAtara extends losses after FDA clinical holdJanuary 21, 2025 | msn.comAtara Biotherapeutics price target lowered to $17 from $21 at CanaccordJanuary 18, 2025 | markets.businessinsider.comBuy Rating for Atara Biotherapeutics Driven by Manufacturing Resolution and Strategic InitiativesJanuary 18, 2025 | markets.businessinsider.comAtara Bio reiterated at Buy by Canaccord on expected Ebvallo manufactureJanuary 17, 2025 | msn.comAtara Shares Sink After FDA Stalls Cancer TreatmentJanuary 16, 2025 | marketwatch.comAtara Biotherapeutics Shares Plunge 38% Following FDA Response to EBVALLO ApplicationJanuary 16, 2025 | sg.finance.yahoo.comAtara announces Ebvallo CRL did not find clinical efficacy deficienciesJanuary 16, 2025 | markets.businessinsider.comAtara Biotherapeutics trading halted, news pendingJanuary 16, 2025 | markets.businessinsider.comAtara stock plummets on FDA setback for EBV drugJanuary 16, 2025 | in.investing.comFDA Rejects Atara's Request to Bring Blood Cancer Treatment to MarketJanuary 16, 2025 | marketwatch.comAtara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)January 16, 2025 | stockhouse.comUS FDA declines to approve Atara Biotherapeutics' cancer therapyJanuary 16, 2025 | reuters.comAtara Biotherapeutics, Inc.'s (NASDAQ:ATRA) high institutional ownership speaks for itself as stock continues to impress, up 27% over last weekJanuary 8, 2025 | finance.yahoo.com Get Atara Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter. Email Address ATRA Media Mentions By Week ATRA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATRA News Sentiment▼1.780.90▲Average Medical News Sentiment ATRA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATRA Articles This Week▼21▲ATRA Articles Average Week Get Atara Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PRME News KOD News BTMD News CRGX News GNFT News CTMX News MNPR News ACIU News AVTE News INBX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ATRA) was last updated on 6/16/2025 by MarketBeat.com Staff From Our PartnersAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredBillionaires are piling into this gold investmentBillionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scra...Weiss Ratings | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atara Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atara Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ATRA Stock Free ATRA Stock Alerts